The big question on investors’ minds is what marijuana stock could be the next to move higher? While there’s no way of knowing with any certainty, one of the industry’s worst-performing stocks of late could actually turn out to be one of its best performers in the months to come. If just a single clinical trial works in favor of Cara Therapeutics (NASDAQ:CARA), it could regain everything it’s recently lost and possibly hit a $1 billion market cap.
Patients in the state of New York suffering from post-traumatic stress disorder will now be able to use medical cannabis to treat PTSD.
While several provinces have announced their plans for recreational cannabis distribution and retail operations, industry stakeholders have been waiting for an announcement on the Canadian cannabis tax framework and that moment has now arrived.
The North American Marijuana Index, a stock index that tracks the top performing cannabis stocks in the U.S. and Canada, increased 4% in October.